Greg Kunst

Greg Kunst

Company: Aurion Biotech

Job title: President & Chief Executive Officer


Focusing in on the Regulatory Landscape for Allogeneic Cell Therapies 3:00 pm

Examining acceptance criteria expectations around gene editing, toxicity, and potency assays Highlighting importance of early CMC work to enable efficient manufacturing scale-up for allogeneic products Evaluating opportunities to align global regulatory perspectives on allogeneic therapiesRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.